BioNTech SE (XTER:22UA)
€ 104.5 5.1 (5.13%) Market Cap: 24.57 Bil Enterprise Value: 8.11 Bil PE Ratio: 0 PB Ratio: 1.25 GF Score: 67/100

BioNTech SE To Present Early Positive Data From Ongoing Phase 1/2 Study of mRNA-Based Vaccine Candidate Against SARS-CoV-2 Call Transcript

Jul 01, 2020 / 03:00PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the BioNTech Conference Call. (Operator Instructions) I must advise you that this call is being recorded today, Wednesday, the 1st of July 2020. And I would now like to hand the call over to the Vice President, Investor Relations and Business Strategy, Sylke Maas. Please go ahead.

Sylke Maas
BioNTech SE - VP of IR and Business Strategy

Thank you for joining us today for BioNTech's conference call to provide preliminary Phase I results for 1 candidate from our BNT162 vaccine program against COVID-19.

You can access the press release issued this morning, as well as the slides that we'll be presenting, by going to the Investors section of our website.

During today's presentation, we will be making several forward-looking statements. These forward-looking statements include, but are not limited to, the timing for enrollment and completion and reporting of data from our ongoing clinical trials. Actual results could differ from those we currently anticipate.

You are,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot